Harrow Inc. Shares Dip as Opaleye Management Sells 5,000 Shares Amid Volatile Sentiment and Mixed Insider Activity

Opaleye Management’s Recent Sell: A Signal or a Blip? On February 27, 2026, Opaleye Management Inc. (the managed‑account owner) sold 5,000 shares of Harrow Inc. at $54.18 each, reducing its post‑transaction holding from 70,000 to 65,000 shares. While the trade amount is modest relative to its overall stake, the timing is noteworthy. The sale occurred shortly after the company’s share price dipped to $52.78, and it coincided with a sharp decline in the market’s weekly performance (–22.59 %) and a highly negative social‑media sentiment score of –56. In the context of a 511 % spike in buzz, the transaction may reflect a tactical pullback amid heightened volatility rather than a fundamental shift in confidence.

What Could This Mean for Investors? Investors should weigh the sell against broader insider activity. In early January, the company’s Chief Commercial Officer purchased 40,000 restricted stock units, while the CEO bought and sold substantial common‑stock blocks in December 2025. These mixed signals suggest that senior executives are still invested in Harrow’s long‑term prospects, albeit with short‑term adjustments. The negative P/E of –375.71 underscores that Harrow is still operating at a loss, so insider moves are often driven by liquidity needs or portfolio rebalancing rather than earnings forecasts. The recent sell therefore does not appear to be a harbinger of a downturn, but rather a response to market pressure and a desire to lock in gains before a potential pullback.

Opaleye Management: A History of Opportunistic Trades Opaleye’s transaction pattern over the past year has been largely “sell‑heavy.” In January 2026, the firm sold 20,000 shares at $53.35, reducing its stake from 90,000 to 70,000 shares. In December 2025, the firm held 3,815,000 shares—a massive position that has remained largely static. Historically, Opaleye tends to liquidate positions when share prices approach or exceed their 52‑week highs, as seen in the January 2026 sale near the $54.85 peak. This behavior aligns with a conservative portfolio strategy focused on capital preservation and opportunistic profit taking, rather than aggressive accumulation.

Implications for Harrow’s Future The company’s upcoming fourth‑quarter and full‑year 2025 results, set for release on March 2, 2026, will be a key catalyst. If earnings improve or the company announces a new ophthalmic drug pipeline, insider buying could surge, potentially reversing the current sell trend. Conversely, if results remain weak, the negative sentiment and high buzz could trigger a broader selloff, affecting even long‑term holders. For investors, the prudent approach is to monitor insider transactions alongside earnings guidance and pipeline updates, keeping in mind that Opaleye’s moves reflect a cautious, liquidity‑centric stance rather than a direct bet on Harrow’s valuation.

Bottom Line Opaleye Management’s recent sale is a small, tactical adjustment in a larger, conservative investment strategy. While the trade signals sensitivity to market volatility and negative sentiment, it does not negate the underlying confidence shown by senior executives or the company’s potential to recover once quarterly results are released. Investors should remain alert to insider activity but also focus on Harrow’s forthcoming financial disclosures and drug development milestones to gauge the company’s true upside.